Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study on remimazolam induction dose in obese vs normal-weight patients
ChiCTR2200056641Phase 4Completed
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam (3 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Total remimazolam induction dose for loss of consciousness. Started Feb 2022; status: completed.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2200056641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056641.